Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935556 · ClinicalTrials.gov registry record
Characterization and Epigenetics of Post-Partum Preeclampsia
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 12
- Enrollment target
NCT02935556: Clinical Trial study, sponsored by Duke University.
NCT02935556 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02935556 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
This study will recruit women with post partum pre-eclampsia and match them to controls without postpartum pre-eclampsia to identify an epigenetic signature that is specific to women with post partum pre-eclampsia to help characterize the underlying pathophysiology of post partum pre-eclampsia.
Interventions
- OTHER no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2022-03-09 |
Why NCT02935556 stopped before completion
NCT02935556 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which no intervention is the first listed.
NCT02935556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02935556 about?
NCT02935556 is a clinical study titled "Characterization and Epigenetics of Post-Partum Preeclampsia". This study will recruit women with post partum pre-eclampsia and match them to controls without postpartum pre-eclampsia to identify an epigenetic signature that is specific to women with post partum pre-eclampsia to help characterize the underlying pathophysiology of post partum pre-eclampsia.
What is the current status of trial NCT02935556?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2017-02-01. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT02935556?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT02935556?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI